Locnartecan

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 593191

CAS#: 1472614-83-7 (free acid)

Description: Locnartecan, also known as PEN-866, Sdc-trap 0063, and STA 12-8666, is a heat shock protein 90 (HSP90) inhibitor-drug conjugates (HDC). STA-12-8666 is binds the tumor-concentrated active form of heat shock protein 90 (HSP90), with a cleavable linker attached to SN-38, the active metabolite of irinotecan. STA-12-8666 selectively binds activated HSP90 and releases its cytotoxic payload resulting in drug accumulation in pancreatic cancer cells in vivo. STA-12-8666 also demonstrated dramatically superior activity in comparison to equimolar doses of irinotecan against 5 patient-derived pancreatic adenocarcinoma xenografts with prolonged remissions in some tumors. Analysis of activity of STA-12-8666 against tumor tissues and matched cell lines demonstrated prolonged accumulation and release of cytotoxic payload in the tumor leading to DNA damage response and cell cycle arrest.

Chemical Structure

img
Locnartecan
CAS# 1472614-83-7 (free acid)
Instruction

Theoretical Analysis

MedKoo Cat#: 593191
Name: Locnartecan
CAS#: 1472614-83-7 (free acid)
Chemical Formula: C49H49N7O9
Exact Mass: 879.36
Molecular Weight: 879.970
Elemental Analysis: C, 66.88; H, 5.61; N, 11.14; O, 16.36

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 2258662-20-1 (sodium)   1472614-83-7 (free acid)    

Synonym: PEN866; PEN-866; PEN 866; STA 12-8666; STA12-8666; STA12-8666; STA 128666; STA 128666; STA128666; Sdc-trap 0063, Locnartecan;

IUPAC/Chemical Name: (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-[2-[5-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-1H-indol-1-yl]ethyl]-1-piperidinecarboxylate

InChi Key: QTPZAEAYDWMVJO-GGCSAXROSA-N

InChi Code: InChI=1S/C49H49N7O9/c1-5-31-33-20-30(8-9-38(33)50-43-35(31)24-55-40(43)22-37-36(45(55)59)25-64-46(60)49(37,63)6-2)65-48(62)54-16-12-27(13-17-54)11-15-53-18-14-28-19-29(7-10-39(28)53)56-44(51-52-47(56)61)34-21-32(26(3)4)41(57)23-42(34)58/h7-10,14,18-23,26-27,57-58,63H,5-6,11-13,15-17,24-25H2,1-4H3,(H,52,61)/t49-/m0/s1

SMILES Code: O=C(N1CCC(CCN2C=CC3=C2C=CC(N4C(C5=CC(C(C)C)=C(O)C=C5O)=NNC4=O)=C3)CC1)OC6=CC=C7N=C8C(CN9C(C(COC([C@@]%10(CC)O)=O)=C%10C=C98)=O)=C(CC)C7=C6

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 879.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Deneka AY, Haber L, Kopp MC, Gaponova AV, Nikonova AS, Golemis EA. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model. PLoS One. 2017 Apr 28;12(4):e0176747. doi: 10.1371/journal.pone.0176747. eCollection 2017. PubMed. PMID: 28453558; PubMed Central PMCID: PMC5409145.


2: Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642. PubMed PMID: 27779106; PubMed Central PMCID: PMC5354841.


3: Heske CM, Mendoza A, Edessa LD, Baumgart JT, Lee S, Trepel J, Proia DA, Neckers L, Helman LJ. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma. Oncotarget. 2016 Oct 4;7(40):65540-65552. doi: 10.18632/oncotarget.11869. PubMed PMID: 27608846; PubMed Central PMCID: PMC5323173.


4: Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7. PubMed PMID: 27267850; PubMed Central PMCID: PMC5065742.


5: Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors. Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13. PubMed PMID: 26271675.